Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data.
Aged
Aged, 80 and over
Cause of Death
Comorbidity
Databases, Factual
Female
Humans
Hypertension, Pulmonary
/ epidemiology
Idiopathic Pulmonary Fibrosis
/ chemically induced
Incidence
Lung Neoplasms
/ epidemiology
Lung Transplantation
/ statistics & numerical data
Male
Medicare Part C
Mortality
Myocardial Infarction
/ epidemiology
Patient Acceptance of Health Care
United States
/ epidemiology
Claims data
Elderly
Idiopathic pulmonary fibrosis
Medicare
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
10 Jan 2019
10 Jan 2019
Historique:
received:
06
07
2018
accepted:
04
12
2018
entrez:
12
1
2019
pubmed:
12
1
2019
medline:
7
5
2019
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a rare life-threating interstitial lung disease (ILD). This study characterizes demographics, health care utilization, and comorbidities among elderly IPF patients and estimates prevalence and incidence rates for selected outcomes. Cohort study using a large US health insurance database (Optum's Medicare Advantage plan). ≥ 1 diagnosis code for IPF (2008 - 2014), age ≥65 years, no diagnosis of IPF or other ILD in prior 12 months. Demographics, health care utilization, comorbidities and incidence rates for various outcomes were estimated. Follow-up continued until the earliest of: health plan disenrollment, death, a claim for another known cause of ILD, or end of the study period. 4,716 patients were eligible; 53.4% had IPF diagnostic testing. Median age was 77.5 years, 50.3% were male, median follow-up time was 0.8 years. Incidence rates ranged from 1.0/1,000 person-years (lung transplantation) to 374.3/1,000 person-years (arterial hypertension). Baseline characteristics and incidence rates were similar for cohorts of patients with and without IPF diagnostic testing. Elderly IPF patients experience a variety of comorbidities before and after IPF diagnosis. Therapies for IPF and for the associated comorbidities may reduce morbidity and associated health care utilization of these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a rare life-threating interstitial lung disease (ILD). This study characterizes demographics, health care utilization, and comorbidities among elderly IPF patients and estimates prevalence and incidence rates for selected outcomes.
METHODS
METHODS
Cohort study using a large US health insurance database (Optum's Medicare Advantage plan).
INCLUSION CRITERIA
METHODS
≥ 1 diagnosis code for IPF (2008 - 2014), age ≥65 years, no diagnosis of IPF or other ILD in prior 12 months. Demographics, health care utilization, comorbidities and incidence rates for various outcomes were estimated. Follow-up continued until the earliest of: health plan disenrollment, death, a claim for another known cause of ILD, or end of the study period.
RESULTS
RESULTS
4,716 patients were eligible; 53.4% had IPF diagnostic testing. Median age was 77.5 years, 50.3% were male, median follow-up time was 0.8 years. Incidence rates ranged from 1.0/1,000 person-years (lung transplantation) to 374.3/1,000 person-years (arterial hypertension). Baseline characteristics and incidence rates were similar for cohorts of patients with and without IPF diagnostic testing.
CONCLUSIONS
CONCLUSIONS
Elderly IPF patients experience a variety of comorbidities before and after IPF diagnosis. Therapies for IPF and for the associated comorbidities may reduce morbidity and associated health care utilization of these patients.
Identifiants
pubmed: 30630460
doi: 10.1186/s12890-018-0759-5
pii: 10.1186/s12890-018-0759-5
pmc: PMC6327584
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Références
Med Care. 1999 May;37(5):436-44
pubmed: 10335746
Am J Med Qual. 1999 Nov-Dec;14(6):270-7
pubmed: 10624032
J Am Soc Nephrol. 2005 Feb;16(2):489-95
pubmed: 15590763
Am J Kidney Dis. 2005 Aug;46(2):225-32
pubmed: 16112040
Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43
pubmed: 17585107
J Clin Hypertens (Greenwich). 2007 Sep;9(9):684-91
pubmed: 17786069
Med Care. 2009 Aug;47(8):916-23
pubmed: 19597373
Dig Dis Sci. 2010 Feb;55(2):328-37
pubmed: 19697131
Ann Pharmacother. 2009 Oct;43(10):1565-75
pubmed: 19706740
Chest. 2010 Jan;137(1):129-37
pubmed: 19749005
Hypertension. 2009 Dec;54(6):1423-8
pubmed: 19858407
Value Health. 2009 Jan-Feb;12(1):34-9
pubmed: 19895371
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40
pubmed: 20935110
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):709-13
pubmed: 21567653
Curr Med Res Opin. 2011 Sep;27(9):1763-8
pubmed: 21793646
Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1150-8
pubmed: 22020901
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:129-40
pubmed: 22262599
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:154-62
pubmed: 22262602
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:222-9
pubmed: 22262609
J Med Econ. 2012;15(5):829-35
pubmed: 22455577
Respir Res. 2013 Aug 21;14:86
pubmed: 23964926
BMC Infect Dis. 2013 Nov 25;13:559
pubmed: 24274680
Drugs Context. 2013 Oct 31;2013:212258
pubmed: 24432045
Ann Thorac Surg. 2015 Aug;100(2):443-51
pubmed: 26070598
Eur Respir J. 2015 Oct;46(4):1113-30
pubmed: 26424523
BMC Pulm Med. 2016 Jan 05;16:2
pubmed: 26732054
Clin Med (Lond). 2016 Feb;16(1):42-51
pubmed: 26833513
Respir Med. 2016 Apr;113:74-9
pubmed: 26915984
J Manag Care Spec Pharm. 2016 Apr;22(4):414-23
pubmed: 27023695
BMC Fam Pract. 2016 Mar 31;17:38
pubmed: 27036116
Am J Epidemiol. 1993 Jan 15;137(2):226-34
pubmed: 8452127